Just In
- 2 hrs ago Kamada Ekadashi 2024 Wishes: Greetings, Messages, Texts, Images, Twitter Status And Instagram Captions
- 3 hrs ago Deepika Padukone's 6 Refreshing Skincare Tips to Beat the Summer Heat
- 8 hrs ago 7 Questions You Should Ask Your Partner Before Getting Into An Arranged Marriage
- 11 hrs ago Heeramandi: Designers Rimple And Harpreet Craft Inspiring 300 Outfits, Know The Details Here!
Don't Miss
- Finance 1:10 Stock Split: 1 Rs 980 Smallcap Has Split Into Ten Shares; Check Out New Price Level, Fundamentals!
- Sports Who Won Yesterday's IPL Match 33? PBKS vs MI, IPL 2024 on April 17: Mumbai Indians Escape Last-Ditched Fight by Punjab Kings To Win
- Movies Do Aur Do Pyaar OTT Release Date & Platform: When & Where To Watch Vidya Balan’s Film After Theatrical Run?
- News BRS Chief K Chandrasekhar Rao Slams BJP, Says K Kavitha's Arrest Is Vendetta Politics
- Automobiles Aprilia RS 457 Accessories: A Detailed Look At The Prices
- Education Karnataka SSLC Result 2024 Soon, Know How to Check Through Website, SMS and Digilocker
- Technology Nothing Ear, Ear a With ANC, Up to 42.5 Hours of Battery Launched; Check Price and Availability
- Travel Telangana's Waterfall: A Serene Escape Into Nature's Marvels
AIIMS Delhi To Start Booster Dose Trial Of Intranasal Covid Vaccine From March 11
The AIIMS will start the booster dose trial of Bharat Biotech's intranasal COVID-19 vaccine from Friday. The booster dose will be given to those who have received both the doses of either Covaxin or Covishield at least five months ago but not more than seven months back, Dr Sanjay Rai, Professor at the Centre for Community Medicine at AIIMS, New Delhi told PTI.
India is yet to approve the use of intranasal vaccine against COVID-19, BBV154 developed by the Hyderabad based company.
The Drugs Controller General of India (DCGI) in January had given permission to Bharat Biotech to conduct a phase-3 randomized, multi-centric study to evaluate the immunogenicity and safety of the booster dose in participants previously vaccinated with Covishield or Covaxin.
"We got the ethical approval for initiating the booster dose trial on Wednesday. Registration for the participants will start from March 10 via email --HYPERLINK "mailto:[email protected]"[email protected] --- and WhatsApp (7428847499) for those who received both the doses of either Covaxin or Covishield more than 5 months but less than 7 months ago," Dr Rai said.
AIIMS, New Delhi is one of the five sites where the booster trial for the nasal vaccine will be conducted.
BBV154 is an intranasal replication-deficient chimpanzee adenovirus SARS-CoV-2 vectored vaccine.
- healthCOVID Surge In India: Do You Need A COVID-19 Booster Shot?
- disorders cureCommon COVID Symptoms In Fully Vaccinated Individuals: What You Should Know
- wellnessMild COVID Linked To Life-Threatening Blood Clots, Increased Risk Of Cardiovascular Disease; Study
- wellnessCOVID-19 Variants In India: New COVID Variant May Pose Threat To Elderly People
- basicsCovid-19 Linked To Early Onset Of Periods: What You Need To Know
- wellnessCOVID XBB Variants Of Omicron In India: What You Should Know
- disorders cureNew Omicron Subvariant BQ.1 Detected In Maharashtra: What You Should Know
- disorders cureWhat Is ‘Centaurus,’ New Fast-Spreading Covid Variant: Everything You Need To Know
- health75 Years Of Independence, 75 Days Of Free COVID Booster Shots; For Everyone Aged 18-59 From 15 July
- wellnessWhat Are The Health Risks Of Getting COVID The Second Or Third Time? 7 Important Points
- wellnessHow Does COVID Spread During Short Conversations?
- wellnessNTAGI To Review Covaxin Corbevax Data For 6-12 Years Thursday, Discuss Reducing Booster Dose Gap